| Effectiveness of state-level vaccination mandates: evidence from the varicella vaccine J Abrevaya, K Mulligan Journal of health economics 30 (5), 966-976, 2011 | 98 | 2011 |
| Access to emergency contraception and its impact on fertility and sexual behavior K Mulligan Health economics 25 (4), 455-469, 2016 | 44 | 2016 |
| Contraception use, abortions, and births: the effect of insurance mandates K Mulligan Demography 52 (4), 1195-1217, 2015 | 39 | 2015 |
| Economic value of anti–vascular endothelial growth factor treatment for patients with wet age-related macular degeneration in the United States K Mulligan, SA Seabury, PU Dugel, JF Blim, DP Goldman, MS Humayun Jama Ophthalmology 138 (1), 40-47, 2020 | 34 | 2020 |
| Value of expanding HCV screening and treatment policies in the United States MT Linthicum, YS Gonzalez, K Mulligan, GA Moreno, D Dreyfus, T Juday, ... Am J Manag Care 22 (6), 227-235, 2016 | 31 | 2016 |
| Do companies in the pharmaceutical supply chain earn excess returns? N Sood, K Mulligan, K Zhong International Journal of Health Economics and Management 21, 99-114, 2021 | 13 | 2021 |
| The value of progression-free survival in metastatic breast cancer: results from a survey of patients and providers JP MacEwan, J Doctor, K Mulligan, SG May, K Batt, C Zacker, ... MDM policy & practice 4 (1), 2381468319855386, 2019 | 12 | 2019 |
| Costs and spillover effects of private insurers' coverage of hepatitis C treatment GA Moreno, K Mulligan, C Huber, MT Linthicum, D Dreyfus, T Juday, ... Am J Manag Care 22 (6), 2016 | 11 | 2016 |
| Evaluating HCV screening, linkage to care, and treatment across insurers K Mulligan, J Sullivan, L Yoon, J Chou, K Van Nuys Am J Manag Care 24 (8), e257-e64, 2018 | 10 | 2018 |
| COVID-19 vaccination mandates for school and work are sound public policy K Mulligan, JE Harris University of Southern California, Leanard D. Schaeffer Center for Health …, 2021 | 8 | 2021 |
| The 340B Drug Pricing Program: Background, Ongoing Challenges and Recent Developments K Mulligan | 5 | 2021 |
| Access to the 340B Drug Pricing Program: is there evidence of strategic hospital behavior? K Mulligan, JA Romley, R Myerson BMC Research Notes 14 (1), 228, 2021 | 5 | 2021 |
| HEALTH TECHNOLOGY ASSESSMENT FOR THE US HEALTHCARE SYSTEM K Mulligan, D Lakdawalla, PJ Neumann, GR Wilensky, DP Goldman, ... | 4 | 2020 |
| Examination of universal purchase programs as a driver of vaccine uptake among US States, 1995–2014 K Mulligan, JT Snider, P Arthur, G Frank, M Tebeka, A Walker, J Abrevaya Vaccine 36 (28), 4032-4038, 2018 | 4 | 2018 |
| What do nonprofit hospitals reward? An examination of CEO compensation in nonprofit hospitals K Mulligan, S Choksy, C Ishitani, JA Romley PloS one 17 (3), e0264712, 2022 | 3 | 2022 |
| New Evidence on the Compensation of Chief Executive Officers at Nonprofit US Hospitals K Mulligan, S Choksy, C Ishitani, JA Romley Medical Care Research and Review 77 (5), 498-506, 2020 | 3 | 2020 |
| Manufacturer Signal-to-Cutoff Threshold Underestimates Cumulative Incidence of SARS-CoV-2 Infection: Evidence from the Los Angeles Firefighters Study O Toubat, AH Berg, K Sobhani, K Mulligan, AM Hori, J Bhattacharya, ... | 2 | 2021 |
| Risk preferences over health: empirical estimates and implications for medical decision-making K Mulligan, D Baid, JN Doctor, CE Phelps, DN Lakdawalla Journal of Health Economics, 102857, 2024 | 1 | 2024 |
| Risk Preferences Over Health: Empirical Estimates and Implications for Healthcare Decision-Making K Mulligan, D Baid, JN Doctor, CE Phelps, DN Lakdawalla National Bureau of Economic Research, 2023 | 1 | 2023 |
| The Broader Economic Value of Treatment for Diabetic Macular Edema K Mulligan, J Kim, B Tysinger, J Blim, G Emerson, PJ Ferrone, JE Kim, ... Diabetes Care 46 (6), 1196-1203, 2023 | 1 | 2023 |
